The administration of RVG-exosomes containing β-site amyloid precursor protein cleaving enzyme (BACE1) siRNA in wild-type mice significantly reduced mRNA and protein levels of BACE1, a key target for therapeutic inhibition of β-amyloid production in Alzheimer’s disease [269]. The gene discussed is BACE1; the disease is Alzheimer disease.